Anal Cancer Treatment: Current Status and Future Perspectives

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Mar 6

PMID 25741135

Citations 27

Authors

Marwan Ghosn

Hampig Raphael Kourie

Pamela Abdayem

Joelle Antoun

Dolly Nasr

Affiliations

Soon will be listed here.

Abstract

Anal cancers (AC) are relatively rare tumors. Their incidence is increasing, particularly among men who have sex with other men due to widespread infection by human papilloma virus. The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage. In local and locally advanced AC, concomitant chemoradiation therapy based on mitomycin C and 5-Fluorouracil (5-FU) is the current best treatment, while metastatic AC, chemotherapy with 5-FU and cisplatin remains the gold standard. There are no indications for induction or maintenance therapies in locally advanced tumors. Many novel strategies, such as targeted therapies, vaccination, immunotherapy and photodynamic therapy are in clinical trials for the treatment of AC, with promising results in some indications.

Citing Articles

SURVIVAL AND PROGNOSTIC FACTORS OF ANAL CANCER: A STUDY BASED ON DATA FROM THE HOSPITAL-BASED CANCER REGISTRY OF A HIGH-COMPLEXITY ONCOLOGY CARE CENTER.

Paixao W, Mendes G, da Silva D, Souza R, Araujo R, Meira K Arq Bras Cir Dig. 2024; 37:e1830.

PMID: 39475885 PMC: 11520677. DOI: 10.1590/0102-6720202400037e1830.

Squamous cell carcinoma of the anus successfully treated with multidisciplinary therapy for metachronous metastatic and local recurrences after DCF chemotherapy: a case report.

Naito R, Shiraishi T, Hosoi N, Watanabe T, Shioi I, Shibasaki Y Surg Case Rep. 2024; 10(1):71.

PMID: 38526705 PMC: 10963677. DOI: 10.1186/s40792-024-01873-2.

Case Report: Resolution of high grade anal squamous intraepithelial lesion with antibiotics proposes a new role for syphilitic infection in potentiation of HPV-associated ASCC.

Ranabhotu A, Habibian N, Patel B, Farrell E, Do J, Sedghi S Front Oncol. 2023; 13:1226202.

PMID: 37854673 PMC: 10580285. DOI: 10.3389/fonc.2023.1226202.

RNA-seq analysis identifies transcriptomic profiles associated with anal cancer recurrence among people living with HIV.

Ye Y, Maroney K, Wiener H, Mamaeva O, Junkins A, Burkholder G Ann Med. 2023; 55(1):2199366.

PMID: 37177979 PMC: 10184583. DOI: 10.1080/07853890.2023.2199366.

Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study.

Atallah R, Zhang Y, Zakka K, Jiang R, Huang Z, Shaib W J Gastrointest Oncol. 2022; 13(5):2306-2321.

PMID: 36388688 PMC: 9660037. DOI: 10.21037/jgo-22-125.

References

Nitori N, Kato Y, Kato A, Deguchi T, Okada A, Kojima M . Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer. Anticancer Res. 2011; 31(11):3983-9. View

Edelman S, Johnstone P . Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2006; 66(1):206-11. DOI: 10.1016/j.ijrobp.2006.03.049. View

Cunin L, Alfa-Wali M, Turner J, Bower M, Ion L, Allen-Mersh T . Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals. Ann Surg Oncol. 2013; 21(2):527-32. DOI: 10.1245/s10434-013-3353-3. View

Schiller D, Cummings B, Rai S, Le L, Last L, Davey P . Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007; 14(10):2780-9. DOI: 10.1245/s10434-007-9491-8. View

Eng C, Chang G, You Y, Das P, Xing Y, Delclos M . Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013; 119(21):3769-75. DOI: 10.1002/cncr.28296. View

James R, Glynne-Jones R, Meadows H, Cunningham D, Myint A, Saunders M . Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013; 14(6):516-24. DOI: 10.1016/S1470-2045(13)70086-X. View

Boman B, MOERTEL C, Oconnell M, Scott M, Weiland L, Beart R . Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer. 1984; 54(1):114-25. DOI: 10.1002/1097-0142(19840701)54:1<114::aid-cncr2820540124>3.0.co;2-p. View

Ajani J, Winter K, Gunderson L, Pedersen J, Benson 3rd A, Thomas Jr C . Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008; 299(16):1914-21. DOI: 10.1001/jama.299.16.1914. View

Schraut W, Wang C, Dawson P, Block G . Depth of invasion, location, and size of cancer of the anus dictate operative treatment. Cancer. 1983; 51(7):1291-6. DOI: 10.1002/1097-0142(19830401)51:7<1291::aid-cncr2820510719>3.0.co;2-r. View

10.

Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J . Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer. 2010; 10:189. PMC: 2887399. DOI: 10.1186/1471-2407-10-189. View

11.

Peiffert D, Seitz J, Rougier P, Francois E, Cvitkovic F, Mirabel X . Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Ann Oncol. 1997; 8(6):575-81. DOI: 10.1023/a:1008295119573. View

12.

Seo Y, Kinsella M, Reynolds H, Chipman G, Remick S, Kinsella T . Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys. 2009; 75(1):143-9. DOI: 10.1016/j.ijrobp.2008.10.046. View

13.

Parkin D . The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118(12):3030-44. DOI: 10.1002/ijc.21731. View

14.

Zampino M, Magni E, Leonardi M, Santoro L, Petazzi E, Fodor C . Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma. BMC Cancer. 2011; 11:55. PMC: 3055231. DOI: 10.1186/1471-2407-11-55. View

15.

Khater R, Frenay M, Bourry J, Milano G, Namer M . Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep. 1986; 70(11):1345-6. View

16.

Gunderson L, Moughan J, Ajani J, Pedersen J, Winter K, Benson 3rd A . Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013; 87(4):638-45. PMC: 3938865. DOI: 10.1016/j.ijrobp.2013.07.035. View

17.

Rughani A, Lin C, Tranmer B, Wilson J . Anal cancer with cerebral metastasis: a case report. J Neurooncol. 2010; 101(1):141-3. DOI: 10.1007/s11060-010-0218-5. View

18.

Hallemeier C, You Y, Larson D, Dozois E, Nelson H, Klein K . Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Dis Colon Rectum. 2014; 57(4):442-8. DOI: 10.1097/DCR.0000000000000071. View

19.

Goto H, Ikenaga M, Yasui M, Miyazaki M, Mishima H, Tsujie M . [A case of salvage treatment for local recurrence of squamous cell anal carcinoma after chemoradiation]. Gan To Kagaku Ryoho. 2011; 37(12):2659-61. View

20.

KLOTZ Jr R, Pamukcoglu T, Souilliard D . Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. Cancer. 1967; 20(10):1727-45. DOI: 10.1002/1097-0142(196710)20:10<1727::aid-cncr2820201024>3.0.co;2-1. View